FOXO4-DRI dosage and evidence

What is FOXO4-DRI?

How does FOXO4-DRI work?

In worn-out cells, it breaks the hold FOXO4 has on p53. That frees p53 to make those cells die off.

What have studies in people found about FOXO4-DRI?

No person has been given FOXO4-DRI. There is no registered trial and no published study in people of any kind. Ads attach it to human studies of drugs that clear out old, worn-out cells, but those studies tested entirely different drugs. And animal research has since turned up a result pointing the other way.

• The human studies of cell-clearing drugs that do exist test pills, not this peptide. NCT04313634 split 74 older adults into groups by chance to test dasatinib, quercetin and fisetin for bone health. NCT04063124 gave dasatinib plus quercetin to 5 people with Alzheimer's disease. Neither used FOXO4-DRI, and neither result carries over to it.
• No registered trials. ClinicalTrials.gov lists no study of FOXO4-DRI, at any stage, anywhere.
• No papers in people. PubMed's 19 records for FOXO4-DRI include no study giving the peptide to a person.
• In a dish, human cells: FOXO4-DRI cleared worn-out cells from human cartilage cells grown in the lab. That is a lab result using human tissue.
• In mice, the first result: a designed peptide that stops two proteins, FOXO4 and p53, from linking up made worn-out cells self-destruct. It restored fitness, fur and kidney function in mice bred to age fast and in naturally old mice.
• In mice, the outside repeat: FOXO4-DRI made worn-out testosterone-making cells self-destruct, and improved testosterone output in old mice.
• In mice and rats, the result that cuts the other way: a 2023 study in Circulation cleared worn-out cells from the lining of lung blood vessels in mice, using a genetic switch, a drug called ABT263, and FOXO4-DRI. Pressure in the lung circulation rose, the right side of the heart thickened, the vessels reshaped, and lung vessel lining cells dropped sharply. In rats given a drug that causes high blood pressure in the lungs, ABT263 eased it slightly at one week and worsened it at three. The authors concluded that clearing these cells may worsen blood flow through the lungs.

What this does not tell you: There is no dose, no route, no half-life, no blood level and no safety record for this peptide in a person. It is a fairly large peptide, about 5 kDa, and at that size the immune system may react to it. Nobody has checked. The mouse results are striking, and they are mouse results. The compound has cleared none of the steps between a mouse and a first study in people. The Circulation study shows that even in animals, whether clearing these cells helps or harms depends on the tissue. So a summary that reports only the good mouse results is not a summary of the evidence.

What do people who took FOXO4-DRI report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• There is very little self-experimentation here and what exists is unusually well documented. The pattern described is a single day of shots under the skin, rising through the session to a total in the tens of milligrams. It follows a plan written out on the forum in advance rather than derived from any human study.
• The outcome reported by the person who did that is no discernible effect of any kind. That is the clearest result in this material and nobody in the discussion reports otherwise.
• Injection problems are described in detail and are the most consistent thing reported: pain during or after the injection depending on the solvent used, swelling at the site lasting about a day, and in some cases the injection being physically expelled back out of the site.
• Cost and sourcing dominate the rest. Figures in the region of ten thousand dollars are quoted for clinical administration, against custom peptide synthesis vendors selling tens of milligrams for a few hundred, and posters openly question whether the cheap material can be the same thing.
• Posters also track that the published versions of the peptide differ in selectivity, with earlier versions described as killing a meaningful fraction of non-senescent cells, and use that to argue that what a vendor ships may not correspond to the version described in the literature.
• The community's own summary is that there was no human data when these experiments were run, which the people running them stated openly.

Sources: Senolytics and group buy threads on LongeCity, reached through site-restricted search extracts of the threads because the site itself would not load from this environment, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2020
  Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

  This finished study tested cell-clearing drugs in people, and FOXO4-DRI was not one of them. 74 older adults were given dasatinib, quercetin and fisetin to see whether clearing worn-out cells helps bone. It is on this page to show what the funded research in people actually tests: older pills that already have human safety records. FOXO4-DRI has no registered trial of its own, so none of this evidence carries over to it.

  A completed Phase 2 in 74 older adults using dasatinib, quercetin and fisetin. Included here because it is what the funded human senolytic field actually tests: repurposed small molecules, not FOXO4-DRI, which has no registered trial of its own.

  NCT04313634 ClinicalTrials.gov, Mayo Clinic
• Animal study2017
  Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

  In mice. The peptide made worn-out cells die. It brought back fitness, fur and kidney function in mice that age fast and in naturally old mice.

  A designed FOXO4 peptide that blocks the FOXO4-p53 interaction selectively triggered apoptosis in senescent cells and restored fitness, fur density and renal function in fast-aging XpdTTD/TTD and naturally aged mice.

  PMID 28340339 Cell
• Animal study2020
  FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice

  In mice. A separate lab found the same effect. In old mice it cleared worn-out testosterone-making cells and raised testosterone.

  Independent replication of the mechanism: FOXO4-DRI induced p53 nuclear exclusion and apoptosis in senescent Leydig cells and improved testosterone secretion in naturally aged mice.

  PMID 31959736 Aging
• Animal study2023
  Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression

  In mice and rats, this is the result that cuts the other way, and it is usually left out. In mice, clearing worn-out cells from lung blood vessels, with FOXO4-DRI among the tools, raised pressure in the lung circulation. It thickened the right side of the heart and stripped out lining cells the lung depends on. In rats, a related cell-clearing drug helped slightly at one week and made things worse by three. The authors warn that clearing these cells may worsen blood flow through the lungs.

  Senescent cell clearance in mice, including with FOXO4-DRI, raised right ventricular systolic pressure and the hypertrophy index, increased vessel remodelling and markedly reduced lung pulmonary endothelial cells. In monocrotaline rats, ABT263 slightly reduced pulmonary hypertension at one week and aggravated it at three. The authors conclude senolytic interventions may worsen pulmonary haemodynamics.

  PMID 36515093 Circulation
• Lab (cells in a dish)2021
  Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

  In a dish. The closest this peptide has come to a person is a dish of human cartilage cells. FOXO4-DRI cleared worn-out cells from human cartilage cells grown in the lab. No person was dosed. Cells taken from people and kept in a dish behave differently from cells inside a living body. Treat this as a sign the idea can work in human cells, and nothing more.

  The closest thing to human data that exists for this peptide: senescent cell removal from expanded human chondrocytes in culture. Human tissue, in a dish, with no person dosed.

  PMID 33996787 Frontiers in Bioengineering and Biotechnology